Lantheus Holdings, Inc. with ticker code (LNTH) now have 8 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $130.00 and $100.00 suggesting an average Analsyt target price of $114.63. Now with the previous closing price of $68.38 this would imply there is now a potential upside of 67.6%. The day 50 moving average is $66.46 and the 200 day moving average is $76.67. The company has a market cap of 4.67B. The current share price for the company is: $68.15 USD
The potential market cap would be $7,824,509,932 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 45.43, revenue per share of $17.66 and a 8.79% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
